Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931269 | 0.84 | ALDH1A1 (0.38) | ATMPOLBLMNASMN1; SMN2 | |
| SCHEMBL7931230 | 0.80 | CHRM1 (0.36) | CHRM1CHRM2SMN1; SMN2 | |
| SCHEMBL9206727 | 0.75 | — | — | |
| SCHEMBL7061157 | 0.70 | ALDH1A1 (0.39) | ATMPOLBLMNAKDM4EMAPT | |
| SCHEMBL12951616 | 0.68 | ALDH1A1 (0.41) | ATMPOLBLMNASMN1; SMN2OPRM1 | |
| SCHEMBL9723156 | 0.67 | ALDH1A1 (0.40) | ATMPOLBLMNAKDM4E | |
| SCHEMBL31536683 | 0.67 | ATM (0.38) | ATMPOLBLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL7930460 | 0.67 | ATM (0.45) | ATMPOLBLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL7929034 | 0.67 | ATM (0.38) | ATMPOLBLMNASMN1; SMN2ABCB11 | |
| SCHEMBL18071114 | 0.66 | F10 (0.40) | ATMPOLBLMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031865-A1 | Substituted 3-phenyluracils | KLINTZ RALF (DE) | 2001-10-18 | — | — | US | disclosed |
| US-6239074-B1 | HERBICIDES, INSECTICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-29 | — | — | US | disclosed |
| EP-0604491-A1 | SUBSTITUTED 3-PHENYLURACILS AS HERBICIDES | BASF Aktiengesellschaft (DE) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993006090-A1 | SUBSTITUTED 3-PHENYLURACILS AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031865-A1 | Substituted 3-phenyluracils | CCR1, CCR6, CCR3 | ATM 1300/4885POLB 2127/4885CHRM1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.